Results 1 to 10 of about 20,325 (194)

Efficacy and safety of aflibercept biosimilars compared to aflibercept in the treatment of neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]

Frontiers in Pharmacology
BackgroundThis study aimed to evaluate the aflibercept biosimilars compared to the reference product aflibercept (Eylea®) in terms of efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).MethodsWe ...
Yating Zhou, Zongyue Zhan, Zixun Wang, Chen Liu   +3 more
doaj   +2 more sources

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report [PDF]

Case Reports in Ophthalmology, 2016
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response
Stacey A. Strong, Avinash Gurbaxani, Michel Michaelides   +2 more
doaj   +5 more sources

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy [PDF]

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +2 more sources

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? [PDF]

Life
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, Franziska Eckardt, Anna Lorger, Viktoria Deiters, Johannes Schiefelbein, Julian Elias Klaas, Benedikt Schworm, Siegfried G. Priglinger, Jakob Siedlecki   +10 more
doaj   +2 more sources

Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion

Molecules, 2022
Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO).
Lasse Jørgensen Cehofski, Anders Kruse, Alexander Nørgaard Alsing, Benn Falch Sejergaard, Jonas Ellegaard Nielsen, Anders Schlosser, Grith Lykke Sorensen, Jakob Grauslund, Bent Honoré, Henrik Vorum   +9 more
doaj   +1 more source

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.

PLoS ONE, 2022
PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama, Riko Matsumoto, Shumpei Obata, Osamu Sawada, Yoshitsugu Saishin, Masashi Kakinoki, Tomoko Sawada, Masahito Ohji   +7 more
doaj   +1 more source

Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy

Journal of Ophthalmology, 2021
Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy.
Vira S. Ponomarchuk, N.I. Molchaniuk, M. M. Umanets   +2 more
doaj   +1 more source

Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]

, 2020
Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery, Bergvall, Caballero, Campochiaro, Cutroneo, de Jong, De Rossi, Evans, Ferrara, Ferrara, Kumar, Lim, Lindquist, McColl, Meyer, Robinson, Sanchez, Sharma, Sheikh, Simó, Steen, Storkebaum, Sultana, Thulliez, Tian, Trifirò, Ueta, Wong, Yasuhara, Ylä-Herttuala, Zachary   +30 more
core   +4 more sources

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]

PLoS ONE, 2015
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin, Fran Milnes   +5 more
doaj   +1 more source

Transient Vision Loss Associated with Prefilled Aflibercept Syringes

Ophthalmology Science, 2022
Purpose: To describe cases of significant vision loss after intravitreal aflibercept administration using prefilled syringes (PFS) and to study the relationships among syringe design, injection speed, and injection force.
Daniel J. Lee, MD, Brittni A. Scruggs, MD, PhD, Erik Sánchez, PhD, Merina Thomas, MD, Ambar Faridi, MD   +4 more
doaj   +1 more source